Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide
In this large sample of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common. The average weight change 1-year post-discontinuation was relatively small; however, there was considerable individual-level variability.
Authors
- Christopher Boyer (ORCID: https://orcid.org/0000-0002-1101-2045)
- Phuc Le (ORCID: https://orcid.org/0000-0003-4788-773X)
- Hamlet Gasoyan (ORCID: https://orcid.org/0000-0002-1627-9777)
- Rebecca Schulte (ORCID: https://orcid.org/0000-0002-0009-8947)
- Nicholas J. Casacchia (ORCID: https://orcid.org/0000-0003-2291-835X)
- Michael B Rothberg
- W. Scott Butsch
- Ali Aminian
- Marcio L. Griebeler
- Bartolome Burguera
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1111/dom.70660
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73